Skip to main content
Premium Trial:

Request an Annual Quote

Yourgene Elucigene DPYD

UK-based Yourgene has launched the Elucigene DPYD assay, a CE-marked chemotoxicity diagnostic test that uses genotyping to identify cancer patients with dihydropyrimidine dehydrogenase (DPD) deficiency. The deficiency causes several and sometimes lethal side effects in patients treated with 5-fluorouracil (5-FU), which is metabolized by the DPD enzyme, encoded by the DPYD gene. Elucigene DPYD, which tests for six common genetic variations, conforms with Clinical Pharmacogenetics Consortium guidelines, which recommend testing for four clinically relevant mutations.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more